Oxidized LDL and anti-oxLDL antibody levels in peripheral atherosclerotic disease

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 6, 2008, Pages 473-478

  Andican, Gülnur ^a,b   Seven, Arzu ^a   Uncu, Murat ^a   Cantaşdemir, Murat ^a   Numan, Furuzan ^a   Burçak, Gülden ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Atherosclerosis; LDL cholesterol; Oxidized low density lipoprotein; oxLDL Ab; Peripheral atherial disease

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY;

ADULT; ANALYTIC METHOD; ANGIOGRAPHY; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING;

ANTIBODIES; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; FEMALE; HEALTH; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RISK FACTORS;

EID: 52949100520     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701842996     Document Type: Article

References (30)

1. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:2243-7.
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
3. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Morooka S. Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardio 2001;37:1871-6.
4. Fang JC, Kinlay S, Behrendt D, Hikita H, Witztum JL, Selwyn AP, et al. Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation. Arterioscler Thromb Vasc Biol 2002;22:2044-8.
5. Erkkilä AT, Närvänenä O, Lehto S, Uusitipa MIJ, Ylä-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:204-9.
6. Hulthe J, Wiklund O, Hurt-Camejo E, Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler Thromb Vasc Biol 2001;21:269-74.
7. Weinbrenner T, Cladellas M, Covas MI, Fito M, Tomas M, Senti M, et al. The SOLOS Study Investigators. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis 2003;168:99-106.
8. van de Vijver LP, Steyger R, van Poppel G, Boer JM, Kruijssen DA, Seidell JC, et al. Autoantibodies against MDALDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 1996;122:245-53.
9. Monaco C, Crea F, Niccoli G, Summaria F, Cianflone D, Bordone R, et al. Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease; pathophysiological implications. Eur Heart J 2001;22:1572-7.
10. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 1995;15:441-5.
11. Grundy SM, Pasternek R, Greenland P, Smith S, Fuster V. Assessment of cardivascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92.
12. Shimada K, Mokuno H, Matsunaga E, Miyazaki T, Sumiyoshi K, MiyauchiK, et al.Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 2004;174:343-7.
13. Homma Y. Predictors of atherosclerosis. J Atheroscler Thromb 2004;11:265-70.
14. Inoue N, Ohara Y, Fukai T, Harrson., DG, Nishida K. Probucol improves endothelial-dependent relaxation and decreases vascular superoxide production in cholesterol-fed rabbits. Am J Med Sci 1998;315:242-7.
15. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844-8.
16. Holvoet P, Jenny NS, Schreiner PJ, Tracy RP, Jacobs DR; for the Multi-Ethnic Study of Atherosclerosis. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2006.
17. Shoji T, Nishizawa Y, Fokumoto M, Shimamura K, Kimura J, Kanda H, et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000;148:171-7.
18. Holvoet P, Macy E, Landeloos M, Jones D, Jenny NS, Van de Werf F, et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem 2006;52:760-4.
19. Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 1999;90:165-72.
20. Lehtimaki T, Lehtinen S, Solavaki T, Nikkila M, Jaakkola O, Jokela H, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:23-7.
21. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, et al. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 1994;14:1892-9.
22. Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 1997;135:161-70.
23. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994;14:32-40.
24. Schumacher M, Eber B, Tatzber F, Kaufmann P, Halwachs G, Fruhwald FM, et al. Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction. Free Radic Biol Med 1995;18:1087-91.
25. Cherubini A, Mecocci P, Senin U, Lowentha DT, Barnert G, Chionne F. Autoantibodies against oxidized low-density lipoproteins in older stroke patients. J Am Geriatr Soc 1997;45:125.
26. de Geest B, Collen D. Antibodies against oxidized LDL for non-invasive diagnosis of atherosclerotic vascular disease. Eur Heart J 2001;22:1517-18.
27. Raitakari OT, Pitkänen O-P, Lehtimäki T, Lahdenperä S, Iida H, Ylä-Herttuala S, et al. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol 1997;30:97-102.
28. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
29. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997;17:3159-63.
30. Craig WY, Poulin SE, Neveux LM, Palomaki GE, Dostal-Johnson DA, Ledue TB, et al. Anti-oxidized LDL antibodies and antiphospholipid antibodies in healthy subjects: relationship with lipoprotein- and oxidation-related analytes. J Autoimmun 1995;8:713-26.